Liminal BioSciences Inc. PFSCF

RE:RE:RE:oups! lmnl cleared since...2019!

[ifso]

Brockinmoney, looks like you have been in a deep coma since two years. Believe it or not, things did happen since this review by the AMF. Turn on your TV and watch the news: Trump isn't president anymore, the Covid did damage all around the world and continue to kill people, and there is a lawsuit against Liminal  (But that, you won't see it on TV: You have to read everything on this forum. I know: That's a lot of efforts for  you). Finally, the review by the AMF wasn't a lawsuit. The lawsuit has been put in place later.

rockymoney wrote:

U do know we can read your posting history.... how come there's no complaint on you?

 

PLITheOne wrote:

 

Hey look at this winner who just showed up here as he feel off the turnip truck..So Stickyscamo you seem to imply that your Newcamo ID was suspended by Stockhouse. I do know that a complaint was lodged to Stockhouse for multiple ID's pumpers on this board. You seem to have first hand knowledge of this which is surprising because you yourself just joined.

Stockhouse and Nasdaq needs to tighten up and come down on fraudsters like you, Stickyscamo, and Liminal!

Just because you can't do any dd and Liminal hides this lawsuit doesn't mean it doesn't exist! 

Let's go baby! It starts very soon!! :)))
Want to see the SP drop? Stay tuned!!  :))

 

rockymoney wrote:

 

no more lawsuit.  By the way,  i read some of your posts plitheone,stockbufoon etc...u do exactly what newcano did, and im sur he could have done to u what u did to him...

AMF Concludes its Review of the Refinancing Transactions Completed by Liminal BioSciences in April 2019

PRNewswire 28-Nov-2019 4:40 PM

LAVAL, QC, ROCKVILLE, MD and CAMBRIDGE, United Kingdom, Nov. 28, 2019 /CNW Telbec/ - Liminal BioSciences Inc. (NASDAQ:LMNL) (TSX:LMNL) ( "Liminal BioSciences" or the "Company" ), a clinical-stage biopharmaceutical company focused on developing novel therapeutics to treat unmet needs in patients with liver, respiratory and kidney disease, acknowledges the press release issued today by the Autorit des Marchs Financiers ("AMF") in which the AMF announced that after a thorough investigation, the AMF has determined that no violation or breach of securities regulation occurred in connection with the refinancing transactions completed by the Company in April 2019. The AMF is the regulatory and oversight body for Qubec's financial sector.

"We are pleased that the AMF has completed its review and concluded that it did not identify any violation or breach of securities regulation in the context of our refinancing transactions", stated Kenneth Galbraith, the Chief Executive Officer of Liminal BioSciences. "We have been cooperative and transparent with AMF throughout the review and look forward to focusing our efforts on developing and commercializing new medicines that may address serious unmet healthcare needs of patients around the world."

In April 2019, the Company completed a series of refinancing transactions, which were subject to the prior review and approval of the Toronto Stock Exchange. On November 18, 2019, the common shares of Liminal BioSciences commenced trading on the NASDAQ Global Market.